Posted by Michael Wonder on 26 May 2021
Woebot Health receives FDA breakthrough device designation for post partum depression treatment
26 May 2021 - WB001 is the first digital therapeutic designed to reduce the burden of post partum depression.
Woebot Heath today announced that the U.S. FDA has granted breakthrough device designation to the company’s digital therapeutic for the treatment of post partum depression.
